Presented at the European Respiratory Society (ERS) congress in Amsterdam were the initial results from the APEX (Asthma Patient Experience on Xoliar) investigation. The results verify that Xolair® (omalizumab) considerably reduces patients need for steroid use, while at the same time managing disease control and lowering the amount of asthma exacerbations.

In the investigation the researchers discovered that omalizumab helps individuals reduce the use of oral steroids; which despite being an effective treatment for patients with severe asthma they are connected with long-term adverse effects, such as weight gain, hypertension, osteoporosis and depression. In the 12 months after patients started on omalizumab (p

In the UK, roughly a quarter of a million individuals suffer from severe asthma and are the heaviest users of health care services. Approximately 80% of the costs for treating patients with asthma is spent on those with the severest symptoms. A smaller group of these individuals will have allergic type asthma, when exposed to allergans, causes an inflammatory response and bronchoconstriction.

The use of healthcare resources were also reduced with the use of omalizumab. Results revealed that the number of accident/emergency visits (70%, 1.5 vs 0.5, 95% CI, p

Similar benefits were observed in individuals on omalizumab who were not receiving continuous oral corticosteroids (n=46) in comparison to individuals who were receiving continuous oral corticosteroids at baseline (n=90).

Written by Grace Rattue